What is ABECMA? ABECMA (idecabtagene vicleucel) is a prescription medicine for the treatment of multiple myeloma in patients who have received at least three kinds of treatment regimens that have not worked or have stopped working. ABECMA is a medicine made from your own white blood cells; the cells are genetically modified to recognize and attack your multiple myeloma cells.
This website is best viewed using the horizontal display on your tablet device.
This website is best viewed using the vertical display on your mobile device.
In a clinical study of 30.9 months follow-up (median), people treated with ABECMA lived longer without the disease getting worse or passing away, 13.8 months vs 4.4 months with standard treatments.
*Median is the middle number in a group of numbers arranged from lowest to highest.
CAR=chimeric antigen receptor.
ABECMA may be a treatment option when multiple myeloma has come back (relapsed) or stopped responding to treatment (refractory) after you have received at least 2 kinds of treatment regimens that include a therapy from each of 3 drug classes.
This includes at least 1 from each of the 3 drug classes below:
You may have been given a combination of these drug types at one time.
Please see product safety information at the respective websites for agents listed above.
While regular check-ins with your healthcare team are still required, the following are NOT required for your multiple myeloma treatment while responding to ABECMA:
*The treatment process includes blood collection, CAR T cell creation, administration, and adverse event monitoring.
You may have heard of or even had a stem cell transplant, which has a different treatment process from ABECMA. ABECMA may be an option even if a stem cell transplant is not.
†Regular check-ins with your healthcare team are still needed.